NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a...
6 insider purchases on record · latest filing 2009-01-21.
Insiders have also filed 1 sale transaction at NGEN.